Enzolytics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENZC research report →
About the company
Enzolytics Inc. , a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses.
- CEO
- Steven Sharabura
- IPO
- 2009
- Employees
- 1
- HQ
- Plano, TX, US
Price Chart
- Market Cap
- $3.55M
- P/E
- -16.80
- P/S
- 0.00
- P/B
- -0.03
- EV/EBITDA
- -29.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.16%
- ROIC
- 0.14%
- Revenue
- $0 · 0.00%
- Net Income
- $-92,239 · 76.59%
- EPS
- $0.00 · 100.00%
- Op Income
- $-82,983
- FCF YoY
- 0.00%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.45
- Avg Volume
- 11.69M
Get TickerSpark's AI analysis on ENZC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ENZC coverage
Recent articles, reports, and earnings notes.
No research on ENZC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENZC report →Similar companies
Peers in the same neighborhood.